Plain-English translation of NCT04918186 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing new immunotherapy combinations for women with platinum-resistant high-grade serous ovarian cancer. The trial is comparing different combinations of medications—including , , , ENB-003, and —to see if they work better than the standard treatment options currently available. Researchers want to understand whether these newer immunotherapy approaches can help patients whose cancer has come back after initial chemotherapy.
Ovarian cancer that comes back quickly after chemotherapy (within 6 months) is very difficult to treat, and current standard options are limited. This trial exists because researchers believe that combining certain immunotherapy drugs might help the body's immune system fight the cancer more effectively in patients who have run out of other treatment options.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive one of the new immunotherapy medication combinations through regular clinic visits. You will also need to undergo tumor biopsies (small tissue samples) before starting treatment and during the study to help researchers understand how the medication is working. The study involves regular check-ups, blood work, and imaging scans to monitor your cancer and watch for any side effects from the medication.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States
Canada